Works matching IS 11745878 AND DT 2022 AND VI 24 AND IP 3
Results: 9
Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 235, doi. 10.1007/s40272-022-00508-z
- By:
- Publication type:
- Article
Diagnosis and Management of Microscopic Colitis in Pediatric Patients.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 217, doi. 10.1007/s40272-022-00504-3
- By:
- Publication type:
- Article
Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 207, doi. 10.1007/s40272-022-00503-4
- By:
- Publication type:
- Article
Hemodynamic Quality Improvement Bundle to Reduce the Use of Inotropes in Extreme Preterm Neonates.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 259, doi. 10.1007/s40272-022-00502-5
- By:
- Publication type:
- Article
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 269, doi. 10.1007/s40272-022-00500-7
- By:
- Publication type:
- Article
Best Evidence-Based Dosing Recommendations for Dexmedetomidine for Premedication and Procedural Sedation in Pediatrics: Outcome of a Risk-Benefit Analysis By the Dutch Pediatric Formulary.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 247, doi. 10.1007/s40272-022-00498-y
- By:
- Publication type:
- Article
Medication and Fluid Management of Pediatric Sepsis and Septic Shock.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 193, doi. 10.1007/s40272-022-00497-z
- By:
- Publication type:
- Article
Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis.
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 185, doi. 10.1007/s40272-022-00496-0
- By:
- Publication type:
- Article
Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr).
- Published in:
- Pediatric Drugs, 2022, v. 24, n. 3, p. 281, doi. 10.1007/s40272-022-00501-6
- By:
- Publication type:
- Article